Can Polycythemia Vera Progress to Myelofibrosis or AML?

For the vast majority of people with Polycythemia Vera (PV), the disease is managed as a chronic condition over decades. While it is natural to fear that the disease will worsen, progression to more aggressive blood cancers is uncommon. Population estimates suggest that the chance of PV progressing to post-PV myelofibrosis (a scarring of the bone marrow) is roughly 5% to 7% at 10 years, and approximately 15% to 20% after 20 years ^[1][2][3]. The risk of developing Acute Myeloid Leukemia (AML) is even lower, generally estimated around 3% at 10 years and remaining in the single digits (4% to 8%) after 20 years ^[4][3][5]. Regular monitoring by your hematology team helps look for changes over time, though it is important to remember these statistics are group averages and do not predict exactly what will happen to any one person.

Interpreting the Numbers

These percentages are broad estimates drawn from different groups of patients over many years. Your individual risk depends on your age, how long you have had PV, and other personal health factors ^[6].

Progression Is Usually a Late Event

Polycythemia vera is a chronic disease, and disease progression typically takes many years. Modern data show that significant changes often do not occur until a decade or more after the initial diagnosis, though in rare cases, changes can happen earlier ^[4][7].

There are two main types of progression that your care team monitors for:

• Post-PV Myelofibrosis (post-PV MF): Over time, progressive changes in the bone marrow’s cells can lead to the buildup of scar tissue (fibrosis). This makes it harder for the marrow to produce healthy blood cells, often causing the body to try making blood in the spleen instead ^[3][8].
• Acute Myeloid Leukemia (AML): A much rarer complication where abnormal, immature blood cells (called blasts) accumulate rapidly. This is a distinctly different disease process from fibrosis, and while the risk climbs slightly the longer a person lives with PV, it remains a rare event overall ^[4][5].

Factors Associated with Progression Risk

Researchers have identified several factors that are associated with a higher likelihood of progression. However, these are population-level associations, not absolute predictions—many people with these risk factors remain stable for decades:

• Age and Disease Duration: Being older at diagnosis and having the disease for a longer time increase the statistical risk ^[6][4].
• Persistent Leukocytosis: A consistently high white blood cell count over time is associated with an increased risk of progression ^[6][9].
• Enlarging Spleen (Splenomegaly): A spleen that continues to grow can be a clue that the bone marrow is struggling, though mild enlargement is common in stable PV ^[6][10].
• High JAK2 Allele Burden: A high proportion of mutated JAK2 genes in your blood cells (the “allele burden”) is linked to a higher risk of developing myelofibrosis. However, there is no universally accepted threshold that predicts individual outcomes ^[11].
• Additional Genetic Mutations: Some patients acquire extra genetic changes in their cancer cells (such as in genes like ASXL1, TP53, or IDH1/2). These mutations can signal a higher risk for myelofibrosis or AML, but broad genetic testing is usually only done when clinically necessary, as results must be carefully interpreted by a hematologist ^[11][12].

How Your Care Team Monitors for Changes

Your routine checkups are individualized and typically include a review of your symptoms, a physical exam (including checking your spleen size), and a complete blood count (CBC) ^[10].

Signs that may prompt your doctor to evaluate you further include:

• Changing Blood Counts: A sudden drop into anemia (low red blood cells) or a falling platelet count can be a clue of progression. However, it is very important to note that these changes are often caused by PV medications (like hydroxyurea or interferon), therapeutic phlebotomy (which causes iron deficiency), or bleeding—they do not automatically mean your disease is progressing ^[13][14].
• New or Worsening Symptoms: An increase in systemic symptoms like drenching night sweats, unexplained fevers, significant weight loss, or severe bone pain ^[15].
• Immature Cells in the Blood: If routine labs show a “leukoerythroblastic” smear (young red and white blood cells appearing in the blood) or circulating blasts, this is a reason for prompt medical review ^[14][16].

If your doctor notices these clues, they may recommend a new bone marrow biopsy or targeted genetic testing ^[17][18]. There is generally no fixed schedule for repeat bone marrow biopsies; they are only performed when blood counts, exams, or symptoms raise a specific medical concern.

Important Safety Note: PV Complications vs. Progression

While monitoring for long-term progression is important, the most immediate risk for anyone with PV is a blood clot, stroke, or heart attack. Do not wait for a routine appointment if you experience sudden chest pain, sudden weakness or numbness, difficulty speaking, severe shortness of breath, a painful swollen leg, or severe bleeding. Seek emergency medical care immediately.